Target intelligence / Profile preview

DNA gyrase subunit A C-terminal domain (GyrA CTD)

Target
GyrA CTD
Molecular classification
Enzyme, Type IIA topoisomerase subunit, DNA-binding protein
01

Overview

The DNA gyrase subunit A C-terminal domain (GyrA CTD) is an essential structural and functional component of bacterial DNA gyrase, the only enzyme capable of introducing negative supercoils into DNA. It possesses a unique 'beta-pinwheel' fold that enables the enzyme to bind and wrap the DNA substrate, a critical prerequisite for the strand-passage reaction that alters DNA topology. By facilitating this wrapping, the GyrA CTD ensures the correct orientation of the G-segment and T-segment of DNA, allowing for efficient supercoiling during replication and transcription. This domain is a major focus for antibacterial drug development because its specific structural architecture is absent in eukaryotic topoisomerases, providing a high degree of therapeutic selectivity. While classic fluoroquinolones primarily target the catalytic N-terminal domain and its interface with GyrB, the CTD is a target for novel inhibitors like Simocyclinone D8, which block the initial DNA-binding and wrapping steps. Mutations within the GyrA CTD or the nearby Quinolone Resistance-Determining Region (QRDR) are primary drivers of clinical antibiotic resistance, necessitating ongoing research into this domain's structural dynamics.

Other names
GyrA-CTDDNA topoisomerase 2 subunit A C-terminal domainBeta-pinwheel domainDNA wrapping domain of GyrA
02

Mechanism of action

Inhibition of the DNA wrapping mechanism essential for negative supercoiling; stabilization of the covalent enzyme-DNA cleavage complex leading to double-strand breaks; prevention of DNA binding to the gyrase complex.

03

Biological functions

DNA wrappingDNA bendingNegative DNA supercoilingDNA replicationDNA transcriptionChromosome compaction
04

Disease associations

InfectionBacterial infectionTuberculosisAnthraxUrinary tract infection
05

Safety considerations

Development of multidrug-resistant (MDR) bacterial strainsCross-reactivity with human topoisomerase II (rare, as the beta-pinwheel fold is unique to bacteria)Tendonitis and tendon rupture associated with fluoroquinolonesCentral nervous system toxicity
06

Interacting drugs

Simocyclinone D8

4 more in the full profile.

07

Biomarkers

GyrA QRDR mutations (e.g., S83L, D87N)GyrA-box mutationsBacterial DNA supercoiling levels

Beyond the preview

Go deeper on DNA gyrase subunit A C-terminal domain (GyrA CTD).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA gyrase subunit A C-terminal domain (GyrA CTD).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call